|View printer-friendly version|
|April 07, 2000 3:23 p.m.|
|Teva & Lundbeck Announce the Successful Completion of a Phase III Trial for a New Treatment for Parkinson's Patients|
JERUSALEM, Israel, April 7, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and H. Lundbeck A/S (CSE: LUN.CO) are pleased to announce the positive results of the phase III clinical trial with rasagiline in Parkinson's disease. The results of this mono-therapy study demonstrate highly significant efficacy in the primary endpoint on progression of parkinsonian symptoms. In addition, rasagiline, a selective irreversible MAO-B inhibitor, was well tolerated in this patient population.